The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): A single institution experience

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2971-2974

  Saif, Muhammad Wasif ^a   Kaley, Kristin ^a   Penney, Robin ^a   Hotchkiss, Susan ^a   Syrigos, Kostas N ^a   Strimpakos, Alexios S ^a  

^a Herbert Irving Cancer Center ^*  (United States)

Author keywords

Capecitabine; Chemotherapy; Colon cancer; Fluorouracil; Gemcitabine

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; GEMCITABINE; MONOCLONAL ANTIBODY; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY;

EID: 80051653055     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259, 2006. (Pubitemid 44305540)
3. Benson AB III: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 13: S5-18, 2007.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
5. Cunningham D and Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26: 6-12, 1999. (Pubitemid 29174244)
6. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J and Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514, 2005. (Pubitemid 43079992)
7. Merl M, Hoimes C, Pham T and Saif MW: Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). Expert Opin Investig Drugs 18: 1257-1264, 2009.
8. Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L and Nicol SJ: Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs, 2010.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
10. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D and Javle MM: A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14: 3202-3209, 2007. (Pubitemid 47594289)
11. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R and Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
12. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL and Ratain MJ: Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20: 582-587, 2002. (Pubitemid 34072543)
13. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G and Giorgi G: Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer 39: 1547-1551, 2003.
14. Bitossi R, Sculli CM, Tampellini M, Alabiso I, Brizzi MP, Ferrero A, Ottone A, Bellini E, Gorzegno G, Berruti A and Dogliotti L: Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 28: 3055-3060, 2008.
15. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F and Kornek GV: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104, 2003. (Pubitemid 36150266)
16. Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G and Francini G: A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 89: 239-242, 2003. (Pubitemid 36976307)
17. Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP and Benson AB III: Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology 66: 303-309, 2004. (Pubitemid 38822800)
18. Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL and McLeod HL: Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol 19: 1742-1748, 2008.